agilon health, inc. revised earnings guidance for the year ended December 31, 2023. For the year, the company expects revenue of $4,295 million to $4,305 million compared to previous guidance of $4,310 million to $4,320 million. Guidance for the fiscal year 2023 excludes MDX Hawaii.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.55 USD | +3.54% | +0.91% | -55.78% |
05-09 | Deutsche Bank Adjusts agilon health Price Target to $5 From $8, Maintains Hold Rating | MT |
05-07 | Transcript : Agilon health, inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.78% | 2.28B | |
-12.75% | 2.95B | |
-21.16% | 2.92B | |
-48.06% | 224M | |
+1.73% | 226M | |
-40.46% | 191M | |
-40.22% | 103M |
- Stock Market
- Equities
- AGL Stock
- News agilon health, inc.
- Agilon health, inc. Revises Earnings Guidance for the Year Ended December 31, 2023